{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Context Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"CNTX"},"Address":{"label":"Address","value":"2001 MARKET STREET, UNIT NO 15,SUITE 3915 SUITE 3915, UNIT NO. 15, PHILADELPHIA, Pennsylvania, 19103, United States"},"Phone":{"label":"Phone","value":"+1 267 225-7416"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (\"TCE\") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Context is headquartered in Philadelphia."},"CompanyUrl":{"label":"Company Url","value":"https://www.contexttherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher Beck","title":"Senior Vice President-Operations"},{"name":"Claudio Dansky Ullmann","title":"Chief Medical Officer"},{"name":"Karen Andreas","title":"Vice President-Clinical Operations"},{"name":"Martin A. Lehr","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}